1. Home
  2. PRAX vs CRL Comparison

PRAX vs CRL Comparison

Compare PRAX & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$312.37

Market Cap

8.8B

Sector

Health Care

ML Signal

HOLD

Logo Charles River Laboratories International Inc.

CRL

Charles River Laboratories International Inc.

HOLD

Current Price

$226.47

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
CRL
Founded
2015
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8B
8.0B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
PRAX
CRL
Price
$312.37
$226.47
Analyst Decision
Strong Buy
Buy
Analyst Count
13
14
Target Price
$397.85
$203.58
AVG Volume (30 Days)
623.7K
679.5K
Earning Date
02-27-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,463,000.00
$4,023,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$14,827.76
$1.70
P/E Ratio
N/A
N/A
Revenue Growth
364.98
N/A
52 Week Low
$26.70
$91.86
52 Week High
$326.91
$228.88

Technical Indicators

Market Signals
Indicator
PRAX
CRL
Relative Strength Index (RSI) 63.20 70.58
Support Level $266.93 $216.03
Resistance Level $326.91 $227.51
Average True Range (ATR) 17.87 7.73
MACD 0.13 0.14
Stochastic Oscillator 75.94 91.22

Price Performance

Historical Comparison
PRAX
CRL

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About CRL Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Share on Social Networks: